MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib

The third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) osimertinib is approved for untreated, or previously EGFR‐TKI–treated T790M‐positive EGFR‐mutated non‐small cell lung carcinoma (NSCLC). We investigated the heterogeneity of responses to osimertinib and its un...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Sci
Huvudupphovsmän: Nishiyama, Akihiro, Takeuchi, Shinji, Adachi, Yuta, Otani, Sakiko, Tanimoto, Azusa, Sasaki, Motoko, Matsumoto, Shingo, Goto, Koichi, Yano, Seiji
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2020
Ämnen:
Drug Discovery and Delivery
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540985/
https://ncbi.nlm.nih.gov/pubmed/32735723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14593
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk